ID: ALA1822922

Max Phase: Preclinical

Molecular Formula: C43H65N5O9

Molecular Weight: 796.02

Molecule Type: Small molecule

Representations

Canonical SMILES:  C=C/C=C\[C@H](C)[C@H](OC(=O)NCCCNC(=O)c1ccc(N=[N+]=[N-])cc1)[C@@H](C)[C@H](O)[C@@H](C)C/C(C)=C\[C@H](C)[C@@H](O)[C@@H](C)/C=C\[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C

Standard InChI:  InChI=1S/C43H65N5O9/c1-10-11-13-27(4)40(57-43(55)46-21-12-20-45-41(53)33-15-17-34(18-16-33)47-48-44)31(8)38(51)29(6)23-25(2)22-28(5)37(50)26(3)14-19-35(49)24-36-30(7)39(52)32(9)42(54)56-36/h10-11,13-19,22,26-32,35-40,49-52H,1,12,20-21,23-24H2,2-9H3,(H,45,53)(H,46,55)/b13-11-,19-14-,25-22-/t26-,27-,28-,29-,30-,31-,32+,35+,36-,37-,38+,39-,40-/m0/s1

Standard InChI Key:  XRAYLROIHMRABV-KMZISQKGSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 796.02

Molecular Weight (Monoisotopic): 795.4782

AlogP: 6.69

#Rotatable Bonds: 22

Polar Surface Area: 223.41

Molecular Species: ACID

HBA: 10

HBD: 6

#RO5 Violations: 3

HBA (Lipinski): 14

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 4

CX Acidic pKa: -10.65

CX Basic pKa:

CX LogP: 5.75

CX LogD: 5.64

Aromatic Rings: 1

Heavy Atoms: 57

QED Weighted: 0.01

Np Likeness Score: 1.59

References

1. Smith AB, Sugasawa K, Atasoylu O, Yang CP, Horwitz SB..  (2011)  Design and synthesis of (+)-discodermolide-paclitaxel hybrids leading to enhanced biological activity.,  54  (18): [PMID:21870795] [10.1021/jm200692n]

2. Nadaradjane C, Yang CH, Rodriguez-Gabin A, Ye K, Sugasawa K, Atasoylu O, Smith AB, Horwitz SB, McDaid HM..  (2018)  Improved Dose-Response Relationship of (+)-Discodermolide-Taxol Hybrid Congeners.,  81  (3): [PMID:29522336] [10.1021/acs.jnatprod.8b00111]

Source

Source(1):

• Scientific Literature